Ovarian cyst regression with levothyroxine in ovarian hyperstimulation syndrome associated with hypothyroidism

Roghieh Molaei Langroudi, Fatemeh Ghazanfari Amlashi1 and Mohammad Hassan Hedayati Emami2

Diagnostic Radiology Department, Poursina Hospital, Guilan University of Medical Sciences, Guilan, Iran, 1Guilan Endocrinology and Metabolism Research Center, Razi Hospital, Rasht, Guilan, Iran and 2Department of Endocrinology, Guilan Endocrinology and Metabolism Research Center, Razi Hospital, Rasht, Guilan, Iran

Correspondence should be addressed to F Ghazanfari Amlashi
Email varash.ghazanfari@gmail.com

Summary

Background: Spontaneous ovarian hyperstimulation syndrome (sOHSS) can occur following hypothyroidism. Ultrasonography facilitates diagnosis and monitoring of this syndrome. We describe ovarian sonographic changes in a hypothyroid patient with sOHSS after treatment with levothyroxine (L-T4).

Case presentation: A 15-year-old girl presented with abdominal pain and distension for a few months. On examination, she had classical features of hypothyroidism. Abdominal and pelvic ultrasound revealed enlarged ovaries with multiple thin-walled cysts and mild ascitic fluid. On follow-up, abdominal ultrasound showed significant reduction of ovary size after 6 weeks of initiation of L-T4. Normal ovary size with complete regression of ovarian cysts was seen after 4 months.

Conclusion: Serial ultrasound in sOHSS associated with hypothyroidism showed regression of ovarian cysts and ovarian volume after 4 months whereas in other studies, it is reported to happen in various durations, presumably according to its etiology.

Learning points:

- OHSS can rarely occur due to hypothyroidism.
- This type of OHSS can be simply treated by L-T4 replacement, rather than conservative management or surgery in severe cases.
- Ultrasound follow-up shows significant regression of ovarian size and cysts within 6 weeks of initiation of L-T4.
- Ultrasound follow-up shows normal ovarian size with complete resolution of ovarian cysts 4 months after treatment.

Background

Ovarian hyperstimulation syndrome (OHSS) is usually iatrogenic and is a potentially life-threatening complication of ovulation induction. Spontaneous OHSS might occur following high levels of human chorionic gonadotropin (HCG) in normal pregnancy, hypothyroidism, or FSH receptor mutation (1). Expanding use of ultrasonography facilitates the diagnosis and monitoring of the treatment of this syndrome (2).

We have described this syndrome in a girl virgin with primary autoimmune hypothyroidism in our previous article (3); we followed her by serial abdominal ultrasound that showed normal ovary size and regression of ovarian cysts after levothyroxine (L-T4) replacement.
Case presentation

A 15-year-old girl presented with abdominal pain and distension for a few months. On examination, she had classical features of hypothyroidism (3). The abdomen was distended and non-tender with a large palpable mass in the lower abdomen extending to the upper abdomen.

Investigation

Laboratory findings included the following: Hb = 11.2 g/dl, Hct = 36.2%, MCV = 81 fl, MCH = 28.2 pg, BUN = 13 mg/dl, Cr = 0.7 mg/dl, cholesterol = 290 mg/dl, and TG = 273 mg/dl. Hormonal studies confirmed hypothyroidism: serum TSH > 100 mIU/l, total T4 = 1.8 μg/dl (normal: 4.4–12.5 μg/dl, radioimmunoassay (RIA)), T3RU = 31.2% (normal: 25–34.4%), anti-TPO antibody = 290 U/ml (normal < 70, ELISA), and prolactin = 176 ng/ml (normal: 3–21, RIA) (3). Abdominal and pelvic ultrasound revealed enlarged ovaries that occupied the whole abdomen and pelvic cavity: right ovary, 150 × 75 × 62 mm with a volume of 454 cc; left ovary, 130 × 70 × 68 mm with a volume of 340 cc. It also represented multiple thin-walled cysts and mild ascitic fluid. Abdominal and pelvic ultrasound showed significant ovarian volume and cyst regression within 4 months of levothyroxine therapy (A) after 2 months, (B) after 4 months, (C) after 8 months (right ovary), and (D) after 8 months (left ovary).

Figure 1
Imaging findings show bilateral multilobulated ovarian cysts. (A) Abdominal ultrasound and (B) abdominal CT scan (3).

Figure 2
Follow-up abdominal sonography showed significant ovarian volume and cyst regression within 4 months of levothyroxine therapy (A) after 2 months, (B) after 4 months, (C) after 8 months (right ovary), and (D) after 8 months (left ovary).

Figure 3
Right and left ovarian volume change after levothyroxine replacement. *Upper digit shows the number of cysts and **lower digit shows the largest diameter of the largest cyst.
Table 1  Summary of case reports describing patients with OHSS associated with hypothyroidism.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Age (years)</th>
<th>Hypothyroidism</th>
<th>Pregnancy</th>
<th>FSH receptor mutation</th>
<th>Sonographic report</th>
<th>Treatment</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hedayati et al.</td>
<td>15</td>
<td>TSH &gt; 100 mIU/l</td>
<td>–</td>
<td>Neg.</td>
<td>Enlarged ovaries with multiple ovarian cysts R: 150×75×62 Lt: 130×70×68 Multiple large cysts with rupture of one cyst R: 110×65 Lt: 110×58</td>
<td>Levothyroxine (100 µg)</td>
<td>After 4 months: normal ovary size and regression of cysts</td>
</tr>
<tr>
<td></td>
<td>14.5</td>
<td>TSH = 72.5 mIU/l</td>
<td>–</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Akbay et al.</td>
<td>21 (P1)</td>
<td>TSH = 8.75 mIU/l</td>
<td>10 weeks</td>
<td>NA</td>
<td>Bilateral multilobulated cystic 130×80 sized ovaries</td>
<td>Levothyroxine (100 µg)</td>
<td>After 3 months of delivery: normal</td>
</tr>
<tr>
<td></td>
<td>23 (P2)</td>
<td>TSH = 2.16 mIU/l</td>
<td>12 weeks</td>
<td>HCG = NI</td>
<td>Bilateral multilobulated cysts R: 13×70 Lt: 110×70</td>
<td>Levothyroxine (100 µg)</td>
<td>After 2 months of delivery: normal</td>
</tr>
<tr>
<td>Dietrich et al.</td>
<td>26 (P1)</td>
<td>Normal</td>
<td>12 weeks</td>
<td>HCG = 118 665</td>
<td>Bilateral multicystic ovaries R: 140×150 Lt: 120×130 Enlarged ovaries R: 100×100 Lt: 100×100</td>
<td>Conservative</td>
<td>Abortion at 15 weeks</td>
</tr>
<tr>
<td></td>
<td>26 (P2)</td>
<td>TSH = 5.51 mIU/l</td>
<td>10 weeks</td>
<td>HCG = 147 688</td>
<td></td>
<td>Levothyroxine (100 µg)</td>
<td>Normal delivery at term</td>
</tr>
<tr>
<td>Lussiana et al.</td>
<td>29</td>
<td>TSH = 5.92 mIU/l</td>
<td>22 weeks (with abortion)</td>
<td>Present (with undetermined significance)</td>
<td>Bilateral multiple ovarian cysts R: 200×110 Lt: 160×120</td>
<td>Levothyroxine (200 µg)</td>
<td>After 3 months of abortion: normal ovaries</td>
</tr>
<tr>
<td>Edwards et al.</td>
<td>30</td>
<td>TSH = 41.7 mIU/l</td>
<td>10 weeks</td>
<td>HCG = 291 206</td>
<td>Enlarged mass</td>
<td>Levothyroxine</td>
<td>By 22 weeks of gestation: ovarian regression 10 weeks after delivery: normal ovaries</td>
</tr>
<tr>
<td>Borna et al.</td>
<td>30</td>
<td>TSH &gt; 400 mIU/l</td>
<td>20 weeks</td>
<td>HCG = NI</td>
<td>Bilateral multilobulated ovarian cysts R: 200×160 Lt: 160×100</td>
<td>Levothyroxine (200 µg)</td>
<td>After 3 months: resolution of cysts</td>
</tr>
<tr>
<td>Sultan et al.</td>
<td>12</td>
<td>TSH = 1310 mIU/l</td>
<td>–</td>
<td>Neg.</td>
<td>Large cystic structure</td>
<td>Levothyroxine (100 µg)</td>
<td>After 6 months: normal ovary size</td>
</tr>
<tr>
<td>Mousavi et al.</td>
<td>26</td>
<td>TSH &gt; 50 mIU/l</td>
<td>–</td>
<td>NA</td>
<td>Bilateral multiseptated ovarian masses R: 69×63×96 Lt: 66×63×99</td>
<td>Levothyroxine (100 µg)</td>
<td></td>
</tr>
</tbody>
</table>
computed tomography (CT) scan showed these thin-walled cysts with no enhancement.

**Treatment**

She was started on l-T4 100 μg/day.

**Outcome and follow-up**

On follow-up ultrasound, the size of the ovaries became significantly smaller 6 weeks after l-T4 replacement and became normal with complete resolution of cysts after 4 months (Figs 1 and 2).

**Discussion**

A description of OHSS in two members of a family has recently been published (3), but there are a few studies focusing on ovarian volume and cyst regression after l-T4 replacement therapy. Imaging findings in OHSS include multiple, large, and thin-walled cysts and ascitic fluid in severe forms (4). The exclusion of diagnosis of ovarian cancer is made by ultrasonography and CT scan or magnetic resonance imaging (MRI), which reveals the classical ‘spoke wheel’ appearance that is characteristic of theca lutein cysts without solid components. Furthermore, the reduction in ovarian volume and regression of detected cysts during close observational management and ultrasonic follow-up can differentiate OHSS from other diagnoses (5).

Here, we described resolution of ovarian cysts and normalization of the size of the ovaries in our patient 4 months after l-T4 administration (Fig. 3). It is noteworthy that the kinetics of the symptoms are closely related to the life span of corpus luteum. In the absence of pregnancy, symptoms resolve spontaneously with the onset of menses, while in the presence of pregnancy, symptoms start to improve after the sixth week of pregnancy, before HCG peak (1). However, in OHSS with underlying disease such as hypothyroidism, complicated pregnancies or in the presence of mutated FSH receptor genes, the symptoms have been reported to last longer (6) (7) (8) (9) (10) (11) (12) (13) (14). Mousavi et al. (6) reported normalization of ovarian appearance in ultrasound 6 months after l-T4 replacement therapy. In other studies on hypothyroid patients (with and without pregnancy), considerable regression of cysts was observed after 3 months (7) (8) (9) (10) (11), with an exception that in three case reports patients experienced total regression 3 months after delivery (12) (13) (14) (Table 1). Rising serum level of
endogenous HCG might strengthen the severity of OHSS in pregnant patients and would lead to a more complicated course than patients with hypothyroidism (15).

In conclusion, ultrasonography as well as CT scan or MRI assists the diagnosis of OHSS. By serial ultrasound, we observed regression of ovarian cysts and ovarian volume after 4 months whereas in other studies, it is reported to happen in various durations that may be related to the etiology of this syndrome.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References